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a  b  s  t  r  a  c  t
Rift  Valley  fever  virus  (RVFV),  a  member  of the  family  Bunyaviridae,  causes  severe  to fatal  disease  in new-
born  ruminants,  as well  as  abortions  in  pregnant  animals;  both  preventable  by  vaccination.  Availability
of  a  challenge  model  is  a pre-requisite  for vaccine  efﬁcacy  trials.  Several  modes  of  inoculation  with  RVFV
ZH501  were  tested  on goats  and  sheep.  Differences  in development  of  infectious  viremia  were  observed
between  animals  inoculated  with  RVFV  produced  in mosquito  C6/36  cells  compared  to Vero  E6  cell-
produced  inoculum.  Only  C6/36-RVFV  inoculation  led to  development  of  viremia  in all  inoculated  sheep
and  goats.  The  C6/36  cell-produced  RVFV  appeared  to be more  infectious  with  earlier onset  of  viremia,iremia
irus  isolation
eal-time RT-PCR
especially  in  sheep,  and  may  also  more  closely  represent  a ﬁeld  situation.  Goats  were  somewhat  more
resistant  to the  disease  development  with  lower  and  shorter  infectious  virus  viremia,  and  with  only  some
animals  developing  transient  increase  in  rectal  temperature  in  contrast  to  sheep.  In conclusion,  a  chal-
lenge  protocol  suitable  for  goat and  sheep  vaccine  efﬁcacy  studies  was  developed  using  subcutaneous
inoculation  of  107 PFU  per  animal  with  RVFV  ZH501  produced  in  C6/36  cells.
Crown Copyright © 2014 Published by Elsevier Ltd.         
  
Open access under CC BY-NC-ND license.. Introduction
Rift Valley fever virus (RVFV) is a member of the family Bun-
aviridae, genus Phlebovirus. This zoonotic arbovirus, endemic to
frica and Arabian Peninsula, causes acute disease in newborn
uminants with up to 100% fatality rate, as well as acute disease in
regnant animals resulting in abortion storms. Naturally infected
nimals develop high viremia sufﬁcient to infect the arthropod vec-
or, even if the infection is inapparent. The economically important
ffected species include sheep, goat, cattle and camel, with the
rimary route of infection being mosquito bites. Humans can be
nfected by mosquito bites, and importantly also by exposure to
lood and tissues of infected ruminants during slaughter, necropsy
r while assisting aborting animals [1,2].
∗ Corresponding author at: National Centre for Foreign Animal Disease, Canadian
ood  Inspection Agency, 1015 Arlington Street, Winnipeg, MB  R3E 3M4, Canada.
el.:  +1 204 789 2027; fax: +1 204 789 2038.
E-mail address: hana.weingartl@inspection.gc.ca (H.M. Weingartl).
ttp://dx.doi.org/10.1016/j.vaccine.2014.02.066
264-410X Crown Copyright © 2014 Published by Elsevier Ltd. Open access under CC BY-NCAlthough the disease and development of viremia in ruminants
is preventable by vaccination, and ruminant vaccination is rec-
ommended to protect human population from RVFV infections,
the number of RVFV vaccines in use is limited [3,4]. Availability
of a reliable challenge model is a pre-requisite for future vaccine
development, registration and licensing. The clinical outcome of
experimental infections of ruminants is dependent on RVFV strain
used for inoculation, animal breed and age, as well as individual
animal variations. The dramatically different clinical outcome of
experimental infections makes vaccine evaluation difﬁcult. There
are currently two  challenge models employed for vaccine efﬁcacy
trials in ruminants, both possessing inherent problems [5–8]. The
abortion model is cumbersome with synchronization of the preg-
nancy and scheduling of high biosecurity facilities. The drawback of
a  viremia model can be a lack of consistency, as not all experimen-
tally inoculated animals may  develop detectable viremia [5,9–11],
although sensitivity of detection may  had been also an issue. For
example Yedloutschnig et al. [12,13] titrated the virus inoculum
for sheep and cattle inoculations in Vero cells, but used more sen-
sitive intraperitoneal inoculation of 4–6 days old mice to detect
viremia in the infected ruminants. Currently, RNA detection is used
-ND license.
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o compensate for the lower sensitivity of virus isolation in cell
ulture.
Different age animals were used in previous studies, ranging
rom one-day-old lambs to several years old adults. Our experimen-
al target age was 3–4 months, when sheep and goats are usually
accinated on farms.
Virus  doses used in the inocula in the reviewed reports were of a
ide range, titrated on different substrates, and therefore difﬁcult
o directly compare. Often, viremia outcome was not in correlation
ith the dose. This may  be possibly related to individual and breed
ariations, and to a low number of animals used in most studies
two to four animals for the same route and dose). Overall it appears
hat lower doses lead to somewhat later development of viremia,
elaying its detection from day one to 2–3 days post inoculation.
n intraperitoneal route of inoculation was often used in the early
xperiments, while more recently subcutaneous route is used in
ajority of studies. Additional or alternative routes have been also
ested, such as mucosal, intravenous, or intradermal inoculation
5–13,15,18,19].
There are very few, older publications on the experimental inoc-
lations of goats, suggesting that the duration of viremia may  be
horter than in sheep: between 1 and 3 dpi, both days inclusive
16,17]. There is one report currently published on vaccine safety
n goats [20], but there are no reports on vaccine efﬁcacy studies in
oats; the second most susceptible ruminant species to Rift Valley
ever virus. Recently, our group started to work on the experimen-
al infections of goats [21], as vaccine immunogenicity, safety and
fﬁcacy testing in this target species may  be also required.
The  aim of this study was to develop a viremia model in goats
nd sheep of vaccine age (3–4 months) suitable for vaccine efﬁ-
acy studies. Up to this point, the RVFV inocula were prepared
sing a substrate of mammalian origin, e.g. sheep and mouse
erum, tissues from infected sheep and mice, or mammalian-
rigin cell cultures, most frequently Vero and BHK cells, regardless
f the origin of the virus isolate [10–18]. To improve the infec-
ion model, virus propagated in Aedes albopictus cells (C6/36)
as compared to virus propagated in mammalian cell line Vero
6. The outcomes of the experimental infections resulting in
 proposed RVFV challenge model for vaccine evaluation are
iscussed.
. Materials and methods
.1.  Cells and viruses
Vero  E6 and C6/36 cells were obtained from American Tissue
ulture Collection. Vero E6 cells were maintained in DMEM/10%
etal bovine serum (Wisent) at 37 ◦C in 5% CO2 incubator. The
6/36 cells were maintained in 47% ESF-921 (Expression Sys-
ems)/47% EMEM/2.5% fetal bovine serum (Wisent)/2.5% HEPES
25 mM ﬁnal)/1% sodium pyruvate (1 mM ﬁnal)(Sigma–Aldrich) at
8 ◦C in sealed ﬂasks (Corning).
RVFV,  strain ZH501 [22], was kindly provided by Dr. Heinz Feld-
ann (National Microbiology Laboratory, Winnipeg). Passage no. 2
as transferred from National Microbiology Laboratory to National
entre for Foreign Animal Disease (NCFAD). The virus was  then
xpanded in Vero E6 cells once, and NCFAD passage two was used
n inoculations with RVFV-Vero E6. NCFAD passage two  was used
o prepare the RVFV-C6/36 stock for animal inoculations. The virus
as sequenced at passage two in Vero E6 cells, and then at passage
our (used for animal infections), and also at passage two  in C6/36
ells (used in animal infections). All three genomic sequences were
onsidered identical, also with the sequence published in GenBank
or RVFV-ZH501. Both virus stocks were characterized on genomic
nd on protein level [21,23]. 32 (2014) 2337–2344
Single virus stock prepared either in Vero E6 cells or C6/36 cells
was used for all respective animal inoculation experiments.
2.2.  Virus plaque titration
The  virus stocks, inocula and sera were plaque-titrated as fol-
lows: 400 l/well of ten-fold serially diluted samples in DMEM
were incubated on conﬂuent monolayers of Vero E6 cells in 12
well plates in triplicates at 37 ◦C in 5% CO2 for 1 h. The inoculum
was replaced by 1.75% carboxymethyl cellulose (Sigma–Aldrich)
in DMEM/0.3% (Wisent) supplemented with 25 mM HEPES
(Sigma–Aldrich)/100 g/ml of Streptomycin/100 IU/ml  of Peni-
cillin (Wisent), and incubated for 4 days at 37 ◦C, 5% CO2. Formalin
(10%) ﬁxed plates were stained with crystal violet (0.5% (w/v) in
80% methanol in PBS), and virus titer determined in PFU/ml.
2.3.  Virus detection
Serum  samples were simultaneously analyzed by virus isolation
using plaque titration as described above to determine viremia, and
by real time RT-PCR to determine virus RNA load.
2.4. One-step real-time RT-PCR
RNA isolation from serum using TriPure (Roche Diagnostics)
according to manufacturer’s instructions was  followed by one-step
real time RT-PCR targeting the L gene [9].
2.5. Antibody detection
Virus  neutralizing antibodies were determined by plaque reduc-
tion neutralization assay as described previously [21] on Vero E6
cells using virus produced in Vero E6 cells.
2.6. Animals
All  animals in this study were 4 months old at the time of inoc-
ulation. Sheep (Suffolk cross, Rideau Arcott cross, Ile-de-France
cross with Rideau Arcott) and goats (Alpine-Boer cross) were
obtained from breeders in Manitoba. All animal manipulations
were approved by the Animal Care Committee of the Canadian Sci-
ence Centre for Human and Animal Health in compliance with the
Canadian Council on Animal Care guidelines (Animal Use Docu-
ments #C-08-007, #C-09-004, #C-10-001, #C-11-011). The work
with infected animals was  performed under containment level 3
conditions (zoonotic BSL-3 Ag).
2.7. Experimental design
Animals  were acclimatized for two  weeks prior to inoculation
and inoculated subcutaneously (SC) with 1 ml  of RVFV (ZH501) into
the right side of the neck, and if applicable re-inoculated SC or
intravenously (IV) depending on the inoculation group. Two doses
were compared: “low” dose of 105 PFU per animal and “high” dose
of 107 PFU per animal. Rectal temperatures were taken for three
days following arrival of the animal to the facility and for mini-
mum of ﬁve days prior to inoculation, and daily during the ﬁrst
week post inoculation. Except for the ﬁrst group (sheep group A;
see below), blood was collected daily for up to 6 or 7 days post inoc-
ulation (dpi). At this time point animals were either euthanized to
determine virus presence in liver and spleen, or were kept up to
35 dpi for serum production, and bled weekly to follow antibody
development (not reported in this manuscript). Overview of the
inoculation groups is provided in Table 1. Where it was  possible to
group animals to compare two experimental approaches, Student’s
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Table  1
Overview of animal inoculation groups.
No. of
animals
Breed Inoc. Dose log10 Route 1 dpi
re-inoculation
Viremia
duration
RNA detection Viremia
Sheep a a
S-A 8 SX Vero 5 SC – ND 8/8 8/8
S-B  4 AR Vero 5 SC – 3 days 3/4 2/4
S-C  4 AR C6 5 SC – 2 4/4 4/4
S-D  4 AR Vero 7 SC – 1 4/4 4/4
S-E  8 AR C6 7 SC – 4 8/8 8/8
S-F  4 AR C6 7 SC SC 4 4/4 4/4
S-G  4 RX C6 7 SC IV 3 4/4 4/4
Goat
G-A  4 BX Vero 5 SC – 2 4/4 4/4
G-B  4 BX C6 5 SC – 2 4/4 4/4
G-C  4 BX Vero 7 SC – 3 4/4 4/4
G-D  4 BX C6 7 SC – 2 4/4 4/4
G-E  4 BX Vero 5 SC IV 2 4/4 4/4
G-F  4 BX C6 5 SC IV 3 4/4 4/4
G-G  4 BX C6 7 SC SC 2 4/4 4/4
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rX, Suffolk cross; AR, cross of Arcott and Rideau; RX, Rideau cross with Ile de France
n  development of viremia); BX, Boer cross. Duration of viremia as determined for i
a Number of animals tested positive/total number of animals in the group.
-test was performed. A P value <0.05 was considered statistically
igniﬁcant.
Sheep: Group S-A: eight animals (Suffolk cross) were inocu-
ated with 105 PFU of RVFV prepared in Vero E6 cells. In this pilot
rial, blood was collected at 3, 5 and 7 dpi. Group S-B: four ani-
als (Rideau Arcott cross) were inoculated with 105 PFU of RVFV
ero E6 stock. Group S-C: four animals (Rideau Arcott cross) were
noculated with 105 PFU of RVFV C6/36-stock. Group S-D: four ani-
als (Rideau Arcott cross) were inoculated with 107 PFU of Vero E6
tock. Group S-E: eight animals (Rideau Arcott cross) were inocu-
ated with 107 PFU of C6/36-stock in two separate trials. Group S-F:
our animals (Rideau Arcott cross) were inoculated with 107 PFU of
6/36 stock and re-inoculated at 1 dpi SC with the same dose. Group
-G: 4 animals (Rideau cross with Arcott or Ile de France) were inoc-
lated with 107 PFU of the C6/36 derived virus stock, followed by
V inoculation with the same dose at 1 dpi.
Most  of the sheep were euthanized at 6–7 dpi, except for few
nimals kept for antibody production for 28 dpi. Some of the ani-
als kept for production of antiserum were boosted at 14 dpi.
Goats: All animals were Boer cross in groups of four. Group G-A
as inoculated with 105 PFU of Vero E6 derived RVFV stock. Group
 G-B was inoculated with 105 PFU of C6/36 derived RVFV stock.
roup G-C was inoculated with 107 of Vero E6 derived virus. Group
-D was inoculated with 107 C6/36 derived RVFV. Group G-E was
noculated with 105 PFU of Vero E6 RVFV stock, and re-inoculated
V with the same inoculum at 1 dpi. Group G-F was  inoculated
ith 105 PFU of C6/36 derived RVFV, and re-inoculated IV with the
ame inoculum at 1 dpi. Group G-G was inoculated with 107 C6/36
erived RVFV and re-inoculated SC with the same inoculum at 1 dpi.
All goats were kept for four weeks following the inoculation
o monitor an antibody development. Serum samples collected at
, 4, 5, 6, 7, 14, 21 and 28–30 dpi were analyzed for presence of
eutralizing antibodies.
.  Results
Differences in susceptibility to RVFV infections were observed
etween sheep and goats, and also between breeds of sheep. In the
rst study, conducted in Suffolk-cross sheep, all animals developed
iremia at 3 dpi, both by virus isolation and RNA detection when
noculated with 105 PFU of virus produced in Vero cells. However,
hen the Rideau Arcott cross lambs were inoculated via the same
oute and the same inoculum, only three out of four animals hade animals were AR, but no apparent differences were observed among the animals
ous virus.
detectable  RVFV RNA in their blood and only two  developed viremia
(Fig. 1). Subsequently different inoculation approaches were tested
to obtain a more reliable viremia model.
Genomic sequences of the inocula were veriﬁed prior to the
start of the animal inoculations. Concurrently with the infection
experiments, characterization on protein level of RVFV generated
in Vero E6 cells or the C6/36 was taking place. There was no dif-
ference in genome of RVFV generated in Vero E6 cells compared to
virus generated in C6/36 cells, including the stock viruses used in
experimental inoculations, and the sequences corresponded with
sequences published for RVFV ZH501 in Gen Bank. Both viruses had
functional NSm and NSs coding genes, as immunoblots of infected
cell lysates indicated that all proteins from the M and S segments
were expressed. The viruses however differed in protein compo-
sition of virions, with the mosquito-cell generated RVFV having
an additional large glycoprotein (78 kDa) incorporated into virions
[23].
3.1. Viremia
Subcutanous inoculation was used in all primary inoculation.
Two doses (105 or 107 PFU/animal) and two  different inocula (pre-
pared either in Vero E6 or in C6/36 cells) were tested. The titer of
inoculum was conﬁrmed by back-titration at the time of inocula-
tion, and stayed within 0.5 log10 difference from the targeted dose.
In speciﬁc groups, attempts were made to increase the viremia by
re-inoculation, either by the subcutaneous or by the intravenous
route at 1 dpi. A summary of the experimental groups is presented
in Table 1.
3.1.1.  Sheep
Using the same mode of inoculation as for the Suffolk breed
(group S-A), the 105 PFU dose of Vero E6 produced RVFV in Rideau
Arcott cross lambs (group S-B) lead to development of viremia only
in three out of four animals at 2 dpi. One sheep appeared to be not
infected based on detection of viremia and viral RNA in serum. This
experiment was conducted concurrently to inoculation with the
same dose of virus produced in the C6/36 insect cells. All animals
inoculated with the insect cells derived virus developed viremia at
1 and 2 dpi supported by viral RNA detection (group S-C, Fig. 1).
Subsequently, a dose of 107 PFU/animal was  tested, again with
both, mammalian (group S-D) or insect (group S-E) cells produced
RVFV. At this dose, the Vero E6 inoculum appeared to be even less
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Fig. 1. Comparison of viremia in sheep inoculated with two  different doses of viruses prepared either in the Vero E6 or the C6/36 cells in individual animals. The inoculation
groups are designated as S-A to S-G, accordingly to Table 1. Two  panels illustrate the difference in viremia between Suffolk-cross sheep (S-A) and Arcott-Rideau-cross sheep
(S-B)  inoculated subcutaneously with 105 PFU per animal of ZH501 RVFV produced in Vero E6 cells. Second panel designated as S-B summarizes viremia in animals inoculated
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rC  with 105 PFU of Vero E6 cells-produced RVFV (ZH501) on a daily sampling basi
-E summarize similarly the inoculations with C6/36 cells-produced virus. Panel S-
olumns  indicate log10 of viral RNA copy numbers per ml  of serum. Black columns i
ffective than the 105 PFU dose based on detection of infectious
irus, although RNA detection in the serum was higher and of longer
uration (Fig. 1, S-B versus S-D). The most effective infection was
chieved by subcutaneous inoculation with 107 PFU of C6/36 cells
roduced virus (group S-E), regardless whether the animals were
e-inoculated subcutaneously with the same dose or not (Fig. 1,pared to group Vero-7 (S-D) with the dose of 107 PFU per animal. Panels S-C and
cated additional SC re-inoculation and panel S-G an additional IV inoculation. Gray
te log10 of PFU/ml of serum.
S-E  and S-F). Virus isolation was successful from serum of all inoc-
ulated animals at 2, 3 and 4 dpi. Intravenous re-inoculation at 1 dpi
appeared to shorten the viremia (Group S-G, Fig. 1). The S-E model
was chosen as a challenge control for efﬁcacy testing of vaccine
candidates [24]. Since the RVFV used in the challenge were the
aliquots of the same virus stock used for this study, we  have added
H.M. Weingartl et al. / Vaccine
Fig. 2. Summary of viremia development in sheep. (A) RVFV viremia in sheep inoc-
ulated with 107 PFU of C6/36 cell-produced virus per animal (n = 8). Solid line – viral
RNA in log10 copy number per ml  of serum, dashed line infectious virus viremia
in  serum in log10 PFU per ml. (B) Comparison of viremia in sheep between groups
inoculated  with Vero E6-derived virus or with C6/36 cell-derived virus. Viremia in
log10 PFU/ml of serum. Solid line inoculum generated in C6/36 cells, dashed line –
inoculum generated in the Vero E6 cells. (C) Comparison of viremia in sheep between
groups inoculated with Vero E6-derived virus or with C6/36 cell-derived virus. Viral
RNA in log10 copy numbers/ml of serum. Solid line inoculum generated in C6/36
c
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tells,  dashed line – inoculum generated in the Vero E6 cells.
n Fig. 2 the results from the four challenge control animals to the
roup to make it statistically stronger (n = 8; Fig. 2A). In order to
e able to perform at least minimal statistical comparison of the
noculation approaches we have grouped animals inoculated with
he Vero E6 produced virus into one group (n = 16), and the ani-
als inoculated with the C6/36 produced virus into a second group
n = 20). Viremia was signiﬁcantly higher in lambs inoculated with
he insect cells produced virus at days 1 and 2 post inoculation 32 (2014) 2337–2344 2341
(P  = 0.03 and P = 0.01, respectively) (Fig. 2B). Correspondingly, the
RVFV RNA levels in serum were also higher in the insect cell virus
inoculated animals (days 1 and 2 post inoculation; P = 0.004 and
P = 0.01 respectively) (Fig. 2C).
3.1.2.  Goats
Several inoculation approaches lead to development of viremia
in all inoculated Alpine-Boer cross goats, although goats were in
general less sensitive to RVFV infection then the sheep based on
infectious virus titers and duration of the viremia. Subcutaneous
inoculation with Vero cells-produced virus lead to development
of viremia either at 2 or 3 dpi (groups G-A and G-E) or between
1 and 3 dpi (groups G-C) (Fig. 3) with maximum duration of two
days. Interestingly, the low dose of Vero-cell produced virus caused
viremia a day later compared to all other inoculation approaches
(groups G-A and G-E)(Fig. 3).
Inoculation with the 107 PFU of C6/36-produced virus (groups
G-D and G-G) lead to development of viremia in all animals at the
same day (1 dpi), making it easier to evaluate (Fig. 3). One goat
in group G-C died suddenly between 1 and 2 dpi without appar-
ent clinical signs, and without increase in rectal temperature (at
1 dpi, the temperature was  39.4 ◦C). There were no pathological
changes found on necropsy, and the virus load was not high com-
pared to typical virus titers recovered from serum, liver, spleen
or other organs and tissues. Cause of death was  therefore consid-
ered as unknown, although it cannot be excluded that the animal
died due to RVFV infection. Statistical comparison of the detected
RVFV RNA levels between goats inoculated with Vero E6-produced
virus (n = 12) and goats inoculated with C6/36 cells-produced virus
(n = 16) indicated that the developed viremia was  higher with faster
onset in animals infected with insect cell-derived virus (P = 0.002)
(Fig. 4A). When the dose 107 PFU/animal of virus of either origin
was evaluated separately, the insect-derived virus caused faster
onset of the viremia, with the signiﬁcantly higher RNA levels at
1 dpi (P < 0.001) (Fig. 4B).
3.2.  Rectal temperatures
Increase  in rectal temperature can be used as one of the parame-
ters in challenge studies in sheep to evaluate efﬁcacy of the vaccine
candidates, but is unfortunately not applicable for goats.
All  RVFV inoculated lambs experienced minimum one or two
days of increased rectal temperatures, with no signiﬁcant differ-
ences between individual inoculation approaches (Fig. 5). On  the
other hand, out of all 28 RVFV inoculated goats only 11 random
animals developed increased rectal temperatures for one day.
3.3.  Neutralizing antibodies
Although  antibody development was not the main focus of the
study, due to limited knowledge on RVFV infection in goats, the
animals were kept for 28–30 dpi, and serum collected during the
animal inoculation experiments was analyzed by plaque reduc-
tion neutralization assay. Development of neutralizing antibodies
against RVFV in goats is summarized in Fig. 6. Signiﬁcant differ-
ence in antibody titers, related to inoculation dose, was  observed
at 14 dpi. Animals infected with 107 PFU of either Vero E6 or C6/36
cell-produced virus developed at least four-fold higher antibody
titers than goats infected with 105 PFU, however a continuous grad-
ual increase in antibody titers until the end of the experiment
was observed in serum of animals inoculated with the lower dose.
Very interestingly, goats infected with high dose of mosquito cell-
produced virus experienced a drop in neutralizing titers by 28 dpi,
while goats infected with the Vero E6 cell-produced RVFV main-
tained their antibody levels at 21 dpi also at 28 dpi.
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Fig. 3. Comparison of viremia in goats inoculated with two  different doses of viruses prepared either in the Vero E6 or the C6/36 cells in individual animals. The inoculation
groups are designated as G-A to G-G, accordingly to Table 1. Panels on the left side summarize inoculations with Vero E6 produced virus inoculated SC with 105 PFU/animal
(G-A), with 107 PFU (G-C) or with 105 PFU followed by IV re-inoculation. The panel on the right side summarize the inoculations with C6/36 derived RVFV (ZH501), using the
dose  of 107 PFU per animal (G-D) and followed by SC re-inoculation (G-G) or using the dose of 105 PFU/animal (G-B) and followed by IV re-inoculation (G-F). Gray columns
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A difference in the onset of antibody response was observed
etween goats and sheep. While serum samples collected at 4 dpi
ere all negative, ﬁrst neutralizing antibodies were detected at
 dpi in 92.5% of goats, and on day 6 post infection all goats sero-
onverted. In comparison, only 85% of sheep seroconverted at 6 dpi,
ith all serum samples collected at 7 dpi being positive for neu-
ralizing antibodies. The antibody titers at 7 dpi for both, goats
nd sheep were about the same, in range of 20–40, for all the
nimals.f PFU/ml of serum.
4. Discussion
The aim of this study was  to develop a viremia model in goats
and sheep of vaccine age (3–4 months) suitable for vaccine efﬁcacy
studies.Low passage RVFV was used for the animal inoculations as high
passage virus in the same cell line may  acquire deletions resulting
in loss of protein expression, e.g. NSs protein, one of the virulence
determinants [25]. In addition, the genomic sequence and protein
H.M. Weingartl et al. / Vaccine 32 (2014) 2337–2344 2343
Fig. 4. Comparison of RNA detection in goats. (A) Virus inoculum derived in Vero
cells is represented by dashed line, C6/36-produced virus is represented by the full
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Fig. 6. Antibody development in goats up to 28 dpi. Goats inoculated with RVFVine. (B) Comparison of the two types of inocula used at the 10 PFU dose. Virus
noculum  derived in Vero cells is represented by dashed line, C6/36-produced virus
s represented by the full line.
xpression were veriﬁed for the virus stock generated in Vero E6
ells as well as for the RVFV stock generated in C6/36 cells [21,23].
Based on the obtained data, both sheep and goats appear to be
ore sensitive to RVFV challenge using virus produced in C6/36 A.
lbopictus mosquito cells compared to Vero E6 cells when adminis-
ered subcutaneously. Besides the intuitive reasoning that the use
ig. 5. Rectal temperatures of sheep inoculated with RVFV ZH501. Temperatures of
nimal inoculated with virus produced in Vero E6 cells are represented by dashed
ine, temperatures of animals inoculated with C6/36-produced virus are represented
y  the full line.produced  in C6/36 cells have gray symbols; goats inoculated with Vero-E6 produced
virus have black symbols. Designation of lines and symbols for individual animal
inoculation  groups is incorporated into the ﬁgure.
of mosquito cell derived virus administered subcutaneously more
closely mimics the ﬁeld transmission of RVFV from mosquitoes to
ruminants than the use of mammalian derived virus or the IV route
of challenge, our previous studies also suggested that the mosquito
cell produced virus may  be more efﬁcient in initiating the infection
via the subcutaneous route. Experimental infection of goats indi-
cated a difference between Vero cell-produced inoculum and the
inoculum produced in C6/36 cells at the immune response level
[21]. RVFV has been shown to infect monocyte-derived dendritic
cells [26]. Current reports on replication of other arboviruses in
dendritic cells, the primary target of these viruses in the host skin,
indicate that there is indeed a biological difference between virus
produced in mammalian cells compared to virus produced in insect
cells in terms of virus–host cell attachment, differential activation
of the dendritic cells and evasion of innate immune response such
as ineffective IFN-type I induction [27–29] resulting in enhanced
infectivity of the mosquito-origin virus for mammalian dendritic
cells compared to mammalian-origin viruses. RVFV, in addition to
presumably different lipid composition of the envelope and dif-
ferent type of glycans on viral glycoproteins, incorporates into the
mosquito-cell matured virions also the large 78 kDa protein [23]
which could further facilitate the interspecies transmission from
mosquitoes to ruminants. We  hypothesized that use of insect cell-
produced RVFV inoculum administered subcutaneously would lead
to consistent and measurable viremia in sheep and goats, repre-
senting a suitable model for veterinary vaccines efﬁcacy studies.
On  the other hand, use of virus inoculum prepared in mam-
malian cells administered via mucosal surfaces [30] appears to
better mimic  human infections acquired through exposure to blood
and tissues of ruminants infected with RVFV, and would be well
suited for human vaccines efﬁcacy studies.
We have also attempted to increase the viremia with different
route of re-inoculation at 1 dpi, in case the early immune response
is partially suppressed by initial virus replication. No observed dif-
ferences may  be due to a late administration of a second dose, and
the model may  be possibly further improved by early re-inoculation
within a shorter period than one day, when the ﬁrst round of virus
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eplication still temporarily suppresses host immune responses
21].
The shorter duration of viremia in goats compared to sheep was
n agreement with previously published data [16,17], and may  be
ossibly accounted to somewhat faster onset of humoral immune
esponse, as one of the species speciﬁc factors. Interesting observa-
ion was made with regard to shorter duration of antibody levels in
oats infected with high dose of mosquito-cell produced virus com-
ared to mammalian-cell produced RVFV, indicating a need for a
ong term study to evaluate performance of serological diagnostic
ests for this species.
In  conclusion, the following challenge protocol was deter-
ined to be suitable for goat and sheep vaccine efﬁcacy
tudies: subcutaneous inoculation into the right side of the
eck with 107 PFU per animal of RVFV ZH501 produced in C6/36
ells.
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